# Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

> **NCT02998996** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eurocine Vaccines AB** · enrollment: 162 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** 15 µg HA/strain and 1% Endocine™
- **BIOLOGICAL:** 15 µg HA/strain and 2% Endocine™
- **BIOLOGICAL:** 15 µg HA/strain
- **BIOLOGICAL:** intramuscular comparator
- **BIOLOGICAL:** intranasal comparator
- **BIOLOGICAL:** Placebo, Saline

## Key facts

- **NCT ID:** NCT02998996
- **Lead sponsor:** Eurocine Vaccines AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-06-01
- **Final completion:** 2017-06-01
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02998996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02998996, "Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02998996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*